European Medicines Agency's workshop on stem cell-based therapies

• Date:
  Monday, 10 May 2010, All day
• Post:
  European Medicines Agency, Amsterdam, the Netherlands

The European Medicines Agency together with the Committee for Advanced Therapies(CAT), the Cell Product Working Party (CPWP) and the Biologics Working Party (BWP) held a workshop to discuss the state-of-the-science on stem cell-based therapies.

Documents

Summary report on the EMA workshop on stem cellbased therapies

Reference Number: EMA/319294/2010

Agenda - Workshop on stem cell-based therapies

Draft Reference Number: EMA/CAT/80413/2010

EU Support for Stem Cell Research, Dr Charles Kessler, EC DG Research

Human Embryonic Stem Cells: Considerations for Therapeutic Product Development, Dr Jane S. Lebkowski, Geron Corporation

Induced pluripotent stem cells: Prof Marc Peschanski, I-stem, Evry, France

Mesenchymal stem cells - Science and therapeutic applications: Dr Dirk Buscher, Grifols

Haematopoietic stem cells: Dr Neil Rodrigues, NIH Centre of Biomedical Research Excellence in Tissue Repair and Stem Cells, USA

Neural stem cells: Prof Gianvito Martino, Division of Neuroscience San Raffaele Hospital, Italy

Stem cell-based medicinal products as ATMPs in the EU: Dr Paula Salmikangas

Stem cell-based medicinal products as ATMPs in the EU: Dr Tiina Palomà¤ki

Overview of Regulation of Stem Cell-based products by the USA FDA: Dr Kimberly Benton, Division of Cellular and Gene Therapies, Office for Cellular, Tissue and Gene Therapy, CBER, FDA

Multimedia